Yigal Fatran - Kadimastem Director
| KDST Stock | ILA 461.60 1.00 0.22% |
Director
Mr. Yigal Fatran serves as Director at Kadimastem Ltd since November 27, 2014. He is member of the Audit and Financial Statements Auditing committees. His work experience includes the following roles Director at electronics Line 3000 Ltd, Together Startup Network Ltd, Medivie Therapeutic Ltd, Investments and Trustees Rishon LeZion Ltd, T R Dermal Ltd and Manager and Marketing Consultant at Amital Direct Mailing Ltd. He holds a BS degree in Economics and Computer Science from BarIlan University. since 2014.
| Age | 65 |
| Tenure | 10 years |
| Phone | 972 73 797 1600 |
| Web | https://www.kadimastem.com |
Kadimastem Management Efficiency
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 11 records | DIRECTOR Age | ||
| Dov Hershberg | Compugen | 74 | |
| Yair Aharonowitz | Compugen | 73 | |
| Arie Ovadia | Compugen | 67 | |
| Ruth Arnon | Compugen | 86 | |
| Eran Perry | Compugen | N/A | |
| JeanPierre Bizzari | Compugen | 64 | |
| Sanford Zweifach | Compugen | 60 | |
| Gilead Halevy | Compugen | 51 | |
| Kinneret Savitsky | Compugen | 50 | |
| Joshua Shemer | Compugen | 63 | |
| Michal Preminger | Compugen | N/A | |
Management Performance
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 |
Kadimastem Leadership Team
Elected by the shareholders, the Kadimastem's board of directors comprises two types of representatives: Kadimastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kadimastem. The board's role is to monitor Kadimastem's management team and ensure that shareholders' interests are well served. Kadimastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kadimastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keren Tzlill, External Director | ||
| Yossi Nizhar, Vice President - Finance | ||
| Ilan Hadar, External Director | ||
| Arik Hasson, Exec Devel | ||
| Yossi BenYossef, Honorary Consultant | ||
| Michal Izrael, VP Diseases | ||
| David Sultan, Independent Director | ||
| Asaf Shiloni, Chief Officer | ||
| Michel Revel, Chief Scientific Officer-Services Provider, Director | ||
| Ram Epstein, Chief Executive Officer, Director | ||
| Joseph Eldor, Director | ||
| Michal Harel, Vice President - Research & Development-ALS & Neurodegenerative Diseases | ||
| Pr MD, Chief CoFounder | ||
| Avi Bzura, External Director | ||
| Abraham Meizler, Director | ||
| Adina Makover, External Director | ||
| Yigal Fatran, Director | ||
| Eli Opper, Chairman of the Board | ||
| Ziv Ironi, External Director | ||
| Neta Lavon, Vice President - Operations | ||
| Julien Ruggieri, Director | ||
| Arye Hasson, Executive Vice President-Research & Development | ||
| Yehuda Feinberg, Vice President - Finance |
Kadimastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kadimastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 38.77 M | |||
| Shares Outstanding | 35.76 M | |||
| Shares Owned By Insiders | 53.72 % | |||
| Shares Owned By Institutions | 8.31 % | |||
| Price To Earning | (167.60) X | |||
| Price To Book | 5.90 X | |||
| EBITDA | (24.48 M) | |||
| Net Income | (26.27 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kadimastem in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kadimastem's short interest history, or implied volatility extrapolated from Kadimastem options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kadimastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Kadimastem Stock analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |